Cyteir Therapeutics
THE CHALLENGE
Need for expert finance and accounting leadership and management. Need for experienced CFO-level guidance and expertise to help prepare for transition from start-up to public company.
THE SITUATION
Cyteir Therapeutics needed cost-effective accounting and finance operations
and CFO-level insights as it moved from fast-growing startup to a public company. It also needed a solid fundraising strategy.
TECHCXO INTERVENTION
TechCXO supported the firm with distinct CFO and other accounting resources to manage all finance and accounting activities from startup to IPO. TechCXO Managing Partner Chris Thomajan became an integral member of the leadership team, providing thoughtful advice based on years of experience in building biotech companies. He interacted with our Board of Directors and investors on a regular basis up to the IPO.
THE OUTCOME
Cyteir Therapeutics had a successful IPO in June of 2021 with a market capitalization in excess of $600M.
“Chris joined us at a crucial time in Cyteir’s development. He and TechCXO helped to transform the company’s financial operations from start-up to public company, which prepared us well for our recent IPO (June 2021). In addition, Chris became a trusted partner and integral member of the leadership team, providing thoughtful advice based on years of experience in building biotech companies. Chris interacted with our Board of Directors and investors on a regular basis and played a key role with our fundraising strategy up to and including the IPO.”
Markus Renschler, MD, President and Chief Executive Officer
Cyteir Therapeutics, Inc.
